Core Viewpoint - NeoGenomics is transitioning from a commodity diagnostic service provider to a comprehensive precision oncology platform, indicating a strategic shift in its business model to enhance its market position and service offerings [1]. Company Strategy - The company is focusing on leveraging first mover advantages in the minimal residual disease (MRD) monitoring sector, which is gaining significant attention in the oncology market [1]. Market Position - The shift towards a precision oncology platform suggests that NeoGenomics aims to differentiate itself from competitors by offering more specialized and advanced diagnostic services [1].